

PANENZA[®], Sanofi Pasteur's Influenza A(H1N1) 2009 Vaccine
INFORMATION NOTE for the DOCTOR/USER
(As per registration of PANENZA HK- 58883 in Hong Kong)

Read this Information Note carefully before you use this product

- This Information Note provides information supplementary to the Package Insert of PANENZA
- Keep this Information Note. You may need to read it again.

The Information Note contains:

1. What PANENZA is and what it is used for
2. How PANENZA is given
3. Further information

1. WHAT PANENZA IS AND WHAT IT IS USED FOR

PANENZA is a vaccine against a pandemic influenza (flu). Pandemic flu is a type of influenza that spreads rapidly around the world. The symptoms (signs) of pandemic flu are similar to those of an ordinary flu but may be more severe. When a person is given the vaccine, the immune system (the body's natural defence system) will produce its own protection (antibodies) against the disease. None of the ingredients in the vaccine can cause flu.

2. HOW PANENZA IS GIVEN

PANENZA is administered by injection into a muscle (usually in the upper arm).

Adults, Elderly (>60 years of age), adolescents and children from the age of 9 years onwards:

One dose (0.5 ml).

Children from 3 years to 8 years of age:

One dose (0.5 ml) is given at an elected date.

A second dose of vaccine should be given after an interval of at least 3 weeks.

Children from 6 months to 35 months of age:

One half-dose (0.25 ml) is given at an elected date.

A second half-dose of vaccine should be given after an interval of at least 3 weeks.

Children less than 6 months of age:

PANENZA is not recommended.

When PANENZA is given as the first dose of a two-dose regime, PANENZA (and not another vaccine against H1N1) should be given as the second dose.

3. FUTHER INFORMATION

The dosage for elderly (>60 years of age) is different from that stated in the Package Insert of PANENZA, which states that Elderly (>60 years of age) should receive two doses of 0.5 ml at least 3 weeks apart. Based on available scientific information and clinical data provided by Sanofi Pasteur, the Scientific Committees of the Centre for Health Protection recommended for persons aged 9 and over, a single 0.5 ml dose of PANENZA be administered to protect against pandemic A(H1N1) 2009 influenza in the Human Swine Influenza Vaccination Programme 2009/10. This recommendation has also been approved for registration of PANENZA in Hong Kong.